Core Viewpoint - Tianpu Co., Ltd. is currently facing regulatory scrutiny from the Shanghai Stock Exchange regarding its main business operations and the qualifications of its senior management, following a significant stock price fluctuation and a notice of investigation from the China Securities Regulatory Commission (CSRC) [1][5]. Group 1: Regulatory Inquiry - On January 14, Tianpu Co., Ltd. received an inquiry letter from the Shanghai Stock Exchange, which requested clarification on the qualifications of newly appointed directors and senior management, as well as their impact on the company's main business operations [1][2]. - The inquiry also demanded an assessment of whether the appointments of personnel from Zhonghao Xinying would affect its independent IPO plans and if there were any significant changes to previously disclosed information [2][3]. Group 2: Stock Performance and Market Reaction - On January 14, Tianpu Co., Ltd. experienced a trading halt and reached its daily price limit, closing at 194.26 yuan per share with a trading volume of nearly 1.2 billion yuan [5]. - Following the resumption of trading on January 12, the stock faced consecutive daily price limits, indicating a negative market reaction to the ongoing regulatory issues [6]. Group 3: Company Response - On January 12, the company issued a clarification announcement addressing false rumors circulating among investors, asserting that the actual controlling person, Yang Gongyifan, had made statements at a public event that were misinterpreted [7].

Core Viewpoint - The company, Jimin Health, has issued a stock trading risk warning as its stock price has experienced significant volatility, with a recent closing price increase leading to concerns about potential rapid declines in the future [1] Summary by Relevant Sections Stock Performance - The company's stock closed at a daily limit increase, with a turnover rate of 16.96% [1] - From September 8 to September 11, 2025, the cumulative closing price increase reached 33.78% [1] - Over the past 30 trading days, the stock's increase has deviated from the Shanghai A-share index by a cumulative 94.72% [1] Trading Anomalies - The stock has shown significant fluctuations, with multiple trading days experiencing consecutive large increases and decreases [1] - There is a clear indication of abnormal trading activity, suggesting potential risks for investors [1] Financial Performance - The company is currently in a state of loss, with no changes in its main business operations [1] - The stock price trend is noticeably diverging from the company's operational performance [1]